Follow The Filings

RZLT Rezolute

Rezolute earnings company data as of 9:01 AM ET 10/23

Scheduled

2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 30 Sep EPS -0.14 — —
Rev — — —

Insider trades

Open-market buys and sales by RZLT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RZLT insider trades
  • $236K bought by 5 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Daron Evans CFO
    Buy
    $29K 10,000 shares at $2.85 +2.5% to stake
    Traded Mar 30 Filed Mar 31
  2. Wladimir Hogenhuis Director
    Buy
    $9,549 5,650 shares at $1.69 +5% to stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
  3. Brian Kenneth Roberts Chief Medical Officer
    Buy
    $48K 28,000 shares at $1.70 +10% to stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
  4. Daron Evans CFO
    Buy
    $80K 45,000 shares at $1.77
    Traded Dec 15, 2025 Filed Dec 15, 2025
  5. Nevan C Elam CEO
    Buy
    $51K 32,000 shares at $1.59 +5.3% to stake
    Traded Dec 15, 2025 Filed Dec 15, 2025
  6. Sunil Ratilal Karnawat Chief Commercial Officer
    Buy
    $20K 12,100 shares at $1.62 +20% to stake
    Traded Dec 15, 2025 Filed Dec 15, 2025

Also filed in the last 12 months, not counted as buying or selling: 10 stock grants and 7 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A
8-K 7.01,9.01
8-K 7.01,9.01
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.